Autres langues Dicot Pharma AB

Actions

Cours en clôture NORDIC GROWTH MARKET Autres places de cotation 00:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,379 ^SEK	-18,32%		-6,88%	+19,18%

06/06	Dicot Pharma AB développe le LIB-01, un médicament d'une nouvelle puissance aux propriétés améliorées par rapport aux médicaments actuellement disponibles	CI
06/05	Dicot AB (publ) publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Dicot Pharma: Experts from Dicot Pharma's clinical study behind submitted abstract	19/06
Experts from Dicot Pharma's clinical study behind submitted abstract	18/06
LIB-01 appears to affect metabolic diseases and Dicot Pharma files new patent application	06/06
Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs	06/06
Today Dicot AB becomes Dicot Pharma AB	30/05
Dicot presents interim report Q1 2024	06/05
Dicot Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Dicot AB has Changed its Name to Dicot Pharma AB	06/05
Good safety and improved erectile function reported from Dicot's phase 1 study	23/04
Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	23/04
Dicot in preparation for clinical phase 2a trial	12/04
Reporting from Dicot's phase 1 study end of April	05/04
BioStock: Dicot's phase I study fully recruited	14/03
Recruitment completed in Dicot's phase 1 trial	11/03
Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial	11/03
Dicot's CEO tells BioStock: "Several prominent people want to be part of the journey"	29/02
Dicot AB Year-End Report 2023	26/02
Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26/02
BioStock: Good safety profile for Dicot's LIB-01	26/01
Positive results from the first part of Dicot's phase 1 study	23/01

Aucun résultat pour cette recherche